--- title: "Abpro Holdings, Inc. (ABPO.US)" type: "Symbol" locale: "zh-HK" url: "https://longbridge.com/zh-HK/quote/ABPO.US.md" symbol: "ABPO.US" name: "Abpro Holdings, Inc." industry: "Biotechnology" datetime: "2026-03-27T21:58:17.585Z" locales: - [en](https://longbridge.com/en/quote/ABPO.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ABPO.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ABPO.US.md) --- > 支持的語言: [English](https://longbridge.com/en/quote/ABPO.US.md) | [简体中文](https://longbridge.com/zh-CN/quote/ABPO.US.md) # Abpro Holdings, Inc. (ABPO.US) ## 公司概況 Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company’s lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. | 項目 | 詳情 | |------|--------| | 行業 | Biotechnology | | 交易所 | US Market | | 官網 | [abpro.co](https://abpro.co) | ## 關鍵驅動因素 > *AI 分析的影響該股票表現的關鍵因素* ## Longbridge Financial Score™: E > *Longbridge Financial Score™ — Longbridge 獨家多因子評級模型* > 更新時間: 2026-03-27T04:30:12.000Z **綜合: E (0.81)** **行業**: Biotechnology | 指標 | 數值 | |--------|-------| | 行業排名 | 375 / 385 | | 行業中位數 | C | | 行業均值 | C | - **風格**: Value - Stocks where the company's main business is in a mature stage. - **規模**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **綜合評分**: E #### Style Score 評分: | 指標 | 數值 | 評級 | |-----------|-------|--------| | Revenue YoY | -100.00% | | | Net Profit YoY | -185.64% | | | P/B Ratio | -0.02 | | | Dividend Ratio | 0.00% | | #### Size Score 評分: | 指標 | 數值 | 評級 | |-----------|-------|--------| | Market Cap | 346053.82 | | | Revenue | 0.00 | | #### Multi Score 評分: E | 指標 | 數值 | 評級 | |-----------|-------|--------| | ROE | 42.31% | A | | Profit Margin | 0.00% | D | | Gross Margin | 0.00% | E | | Revenue YoY | -100.00% | E | | Net Profit YoY | -185.64% | E | | Total Assets YoY | -49.54% | E | | Net Assets YoY | -31.03% | E | | Cash Flow Margin | 0.00% | D | | OCF YoY | -100.00% | E | | Turnover | 0.00 | E | | Gearing Ratio | 1015.74% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Abpro Holdings, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-100.00%", "rating": "" }, { "name": "Net Profit YoY", "value": "-185.64%", "rating": "" }, { "name": "P/B Ratio", "value": "-0.02", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "346053.82", "rating": "" }, { "name": "Revenue", "value": "0.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "E", "indicators": [ { "name": "ROE", "value": "42.31%", "rating": "A" }, { "name": "Profit Margin", "value": "0.00%", "rating": "D" }, { "name": "Gross Margin", "value": "0.00%", "rating": "E" }, { "name": "Revenue YoY", "value": "-100.00%", "rating": "E" }, { "name": "Net Profit YoY", "value": "-185.64%", "rating": "E" }, { "name": "Total Assets YoY", "value": "-49.54%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-31.03%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "0.00%", "rating": "D" }, { "name": "OCF YoY", "value": "-100.00%", "rating": "E" }, { "name": "Turnover", "value": "0.00", "rating": "E" }, { "name": "Gearing Ratio", "value": "1015.74%", "rating": "E" } ] } ] } ``` ## 估值分析 | 指標 | 當前值 | 行業排名 | 最高 | 中位 | 最低 | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.02 | 78/385 | - | - | - | | PB | -0.02 | 460/385 | - | - | - | | Dividend Yield | 0.00% | - | - | - | - | ## 同業比較 | 排名 | 名稱 | 盈利 | 成長 | 營運 | 財務安全 | 現金流 | 評級 | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | MiMedx (MDXG.US) | A | B | A | B | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A | | 04 | CapForce Inc. (CFOR.US) | B | A | A | B | B | A | | 05 | OpGen (OPGN.US) | B | A | A | B | B | A | ## 參考連結 - [公司概況 — 簡介、高管、股東、業務構成](https://longbridge.com/zh-HK/quote/ABPO.US/overview.md) - [財務報表 — 損益表、資產負債表、現金流、分紅方案](https://longbridge.com/zh-HK/quote/ABPO.US/norm.md) - [相關新聞](https://longbridge.com/zh-HK/quote/ABPO.US/news.md) - [公告 — 公司公告與監管文件](https://longbridge.com/zh-HK/quote/ABPO.US/filings.md) --- > **免責聲明: 本文僅供參考，不構成任何投資建議。**